{"title":"New product intros (darinaparsin, eladocagene exuparvovec, fexuprazan hydrochloride, nemolizumab (first-in-class), pimitespib, tirzepatide (first-in-class))","authors":"","doi":"10.1358/dot.2022.58.10.3487255","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2022.58.10.3487255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
新产品引进(darinparsin、eladocagene exuparvovec、盐酸非特普拉赞、奈莫单抗(同类首创)、吡咪司匹、替西帕肽(同类首创))
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
